Complexity of interactions between voriconazole and antiretroviral agents

Annals of Pharmacotherapy

Volumn 42, Issue 5, 2008, Pages 698-703

  Yakiwchuk, Erin M ^a   Foisy, Michelle M ^a,c   Hughes, Christine A ^a,b  

^a Capital Health Edmonton   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROYAL ALEXANDRA HOSPITAL   (Canada)

Author keywords

Drug interaction; Ritonavir; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; CASPOFUNGIN; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LIVER ENZYME; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PLACEBO; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNINDEXED DRUG; VORICONAZOLE;

AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; BIBLIOGRAPHIC DATABASE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; EMBASE; ESOPHAGUS CANDIDIASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; LIVER FUNCTION; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; PATIENT MONITORING; PRIORITY JOURNAL; PUBLICATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANTI-RETROVIRAL AGENTS; DRUG INTERACTIONS; HUMANS; PYRIMIDINES; TRIAZOLES;

EID: 42949134548     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K530     Document Type: Review

References (25)

1. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45:649-63. DOI 10.2165/00003088-200645070-00002
2. Package insert. VFEND (voriconazole). Kirkland, QC: Pfizer Canada Inc., August 2004.
3. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31. DOI 10.1086/374557
4. Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006;27:274-84. DOI 10.1016/j.ijantimicag. 2006.01.003
5. Mikus G, Schowel V, Drzewinska M, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80:126-35. DOI 10.1016/j.clpt.2006.04.004
6. Donnelly JP, De Pauw BE. Voriconazole - a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect 2004;10(suppl 1):107-17.DOI 10.1111/j.1470-9465.2004.00838.x
7. Purkins L, Wood N, Kleinermans D, Love ER. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 2003;56:62-8. DOI 10.1046/j.1365-2125.2003. 02001.x
8. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60. DOI 10.1097/01.qai.0000219774.20174.64
9. Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007;51:3617-26. DOI 10.1128/AAC.00526-07
10. Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001;41:535-67.
11. Package insert. Norvir (ritonavir). Chicago, IL: Abbott Laboratories, January 2006.
12. Package insert. VFEND (voriconazole). New York, NY: Pfizer Inc., November 2006.
13. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570-2. DOI 10.1128/AAC.50.4. 1570-1572.2006
14. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43:S28-39. DOI 10.1086/504492
15. Cato A III, Cao G, Hsu A, Cavanaugh J, Leonard J, Granneman R. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab Dispos 1997;25:1104-6.
16. Package insert. Cancidas (caspofungin). Pointe-Clare Dorval, QC: Merck-Frosst Ltd., January 2006.
17. Package insert. Aptivus (tipranavir). Burlington, ON: Boehringer Ingelheim Canada Ltd., April 2007.
18. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2007; 1-143. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 2007 Dec 3).
19. Scherpbier HJ, Hilhorst MI, Kuijpers TW. Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. Clin Infect Dis 2003;37:828-30. DOI 10.1086/376985
20. Package insert. Sustiva (efavirenz). Montreal, QC: Bristol-Myers Squibb Canada, June 2007.
21. Package insert. Viramune (nevirapine). Burlington, ON: Boehringer Ingelheim Canada, July 2007.
22. Package insert. Selzentry (maraviroc). New York, NY: Pfzer Inc., August 2007.
23. Kassahun K, McIntosh I, Hreniuk D, et al. Absorption, metabolism, and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers (abstract A:372). Presented at 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
24. Kakuda TN, Scholler-Gyure M, Woodfall BJ, et al. TMC 125 in combination with other medications: summary of drug-drug interactions. Presented at 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 12-26, 2006.
25. Package insert. Intelence (etravirine). Raritan, NJ: Tibotec Therapeutics, Division of Ortho Biotech Products, January 2008.